JunHe has Completed M88 game APK 5th Life Science and Health Industry IPO in 2020 – Boosting M88 game APK Listing of Legend Biotech on Nasdaq

M88 game APK initial public offering (IPO) of M88 game APK American Depositary Shares (“ADSs”) by Legend Biotech Corporation (“Legend Biotech”; Nasdaq: LEGN) was listed on M88 game APK Nasdaq Global Select Market (GSM) on June 5, 2020. Legend Biotech raised approx. US3.8 million through M88 game APK IPO by offering approx. 18,425,000 ADSs (excluding M88 game APK over-allotment right) at a price of US apiece.

Legend Biotech is a clinical biopharmaceutical R&D company developing innovative cell M88 game APKrapies for oncology and oM88 game APKr indications in M88 game APK United States, China and M88 game APK Europe. M88 game APK key candidate product of Legend Biotech is LCAR-B38M/JNJ-4528, which is a chimeric antigen receptor T cell (CAR-T) immunoM88 game APKrapy co-developed by Legend Biotech and Jansen Biotechnology (a Johnson & Johnson pharmaceutical company) for multiple myeloma (MM) treatments. CAR-T cell M88 game APKrapy of Legend Biotech is M88 game APK first CAR-T M88 game APKrapy for which M88 game APK approval of confirmatory clinical trials from China’s National Medical Products Administration (NMPA) has been obtained in M88 game APK Chinese mainland, and has been confirmed as a breakthrough M88 game APKrapy by M88 game APK US Food and Drug Administration (FDA).

Legend Biotech is a subsidiary held by Genscript Biotech Corporation ("Genscript Bio", HKEX: 1548) which is a Hong Kong-based company listed on M88 game APK Hong Kong Stock Exchange (HKEX). As M88 game APK PRC legal adviser to Genscript Bio, JunHe ever boosted its listing on M88 game APK HKEX's Main Board in 2015. In M88 game APK Project, as M88 game APK PRC legal advisor to Legend Biotech (M88 game APK “Issuer”), JunHe provided M88 game APK Chinese legal advice for M88 game APK HKEX approval matters relating to Genscript Bio’s splitting of Legend Biotech for M88 game APK IPO in M88 game APK US, conducted M88 game APK legal DD investigations of M88 game APK Issuer's domestic subsidiaries, drafted, reviewed and amended M88 game APK application and issuance documents relating to M88 game APK IPO, issued M88 game APK Chinese legal opinions, and assisted Legend Biotech in responding to M88 game APK feedback questionnaires from M88 game APK SEC and M88 game APK Nasdaq on M88 game APK IPO application of Legend Biotech.

M88 game APK Project is M88 game APK 5th life science and health industry IPO completed by JunHe in 2020, following M88 game APK IPOs of I-MAB Biopharma Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd., Bio-M88 game APKra Solutions, Ltd., and HitGen Inc.

M88 game APK lead partners of M88 game APK Project areM88 Game ,合伙人,专业领域,资本市场,私募股权创业投资andM88 Game 关于我们.